[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543375":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":14,"locations":20,"responsibleParty":41,"collaborators":44,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":78,"overallStatus":23,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Jena University Hospital","OTHER",[8,11],{"label":9,"type":10,"description":10,"interventionNames":10},"Patients receiving ultrahypofractionated radiotherapy",null,{"label":12,"type":10,"description":13,"interventionNames":10},"Retrospective reference cohort","reference cohort of patients who underwent normofractionated radiotherapy or moderately hypofractionated radiotherapy earlier.\n\nmatching 1:1:1 by tumor stage and risk profile (d'Amico)",[15],{"name":16,"role":17,"phone":18,"phoneExt":10,"email":19},"Klaus Pietschmann, MD. MBa. LLM.","CONTACT","00 - 49 03641 - 9-328401","strahlentherapie@med.uni-jena.de",[21],{"facility":22,"status":23,"city":24,"state":10,"zip":10,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Department of Radiotherapy and Radiation Oncology, Jena University Hospital","RECRUITING","Jena","Germany","DE",{"type":28,"coordinates":29},"Point",[30,31],11.5899,50.92878,{"lat":31,"lon":30},[34,38],{"name":35,"role":17,"phone":36,"phoneExt":10,"email":37},"Klaus Pietschmann, MD","+4936419328401","klaus.pietschmann@med.uni-jena.de",{"name":39,"role":40,"phone":10,"phoneExt":10,"email":10},"Georg Wurschi, MD","PRINCIPAL_INVESTIGATOR",{"type":40,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Georg Wurschi","Principal Investigator",[45,47,50,52,54,56],{"name":46,"class":6},"Klinikum Stuttgart",{"name":48,"class":49},"University Medical Center Göttingen","UNKNOWN",{"name":51,"class":6},"Kantonsspital Aarau",{"name":53,"class":49},"Hirslanden Stephanshorn",{"name":55,"class":49},"Radiologische Allianz Hamburg",{"name":57,"class":6},"University Hospital Freiburg","100543375","ultrahypofractionated-adaptive-radiation-therapy-of-prostate-cancer-100543375",false,"NCT06355050","Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer","Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer - Ultra-HART","ultraHART","Inclusion Criteria:\n\n* no androgen deprivation therapy within the last 2 months prior to RT\n* good performance status (Eastern Cooperative Oncology Group, ECOG, 0\u002F1)\n* no secondary malignancy","MALE","18 Years","120 Years",{"count":70,"type":71},150,"ESTIMATED","OBSERVATIONAL","In this prospective, multi-center cohort study, the tolerability and quality of life during ultrahypofractionated radiotherapy (RT) of early stage prostate cancer is surveyed at several institutions in Germany. Radiotherapy is delivered by an online-adaptive RT device (Varian Ethos), which is able to correct daily variations in anatomy and to adjust the irradiation plan accordingly. A digital patient questionnaire is used to asses quality of life longitudinally. Quality of life (QoL) and toxicity profiles will be correlated with planning parameters and compared to retrospective cohorts of patients who underwent normofractionated RT or moderately hypofractionated RT, respectively.",[75,76,77],"Prostate Cancer","Adaptive Radiotherapy","Quality of Life",[76,77,79],"Ultra-hypofractionation","2026-06-09",{"date":82,"type":83},"2026-06-11","ACTUAL",{"date":85,"type":83},"2026-04-01",{"date":87,"type":71},"2032-09-30",{"name":5,"class":6},1]